Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
The two studies will be conducted at 15 sites in the country, primarily in England and Scotland.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
One of the trials will involve patients with moderate symptoms and the other will enrol patients in a serious condition.
